Lupin announced that its subsidiary Lupin Pharmaceuticals has received final approval for its Lorazepam oral concentrate USP, 2 mg/mL from the United States Food and Drugs Administration (US FDA) to market a generic version of Lorazepam Intensol, 2 mg/mL, of Roxane Inc.
Lupin’s Lorazepam oral concentrate USP, 2 mg/mL is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
Lorazepam oral concentrate had annual US sales of approximately $10.7 million (IMS MAT September 2012 sales).
EP News Bureau – Mumbai
- Advertisement -
